ATE435302T1 - Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken - Google Patents

Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Info

Publication number
ATE435302T1
ATE435302T1 AT03747881T AT03747881T ATE435302T1 AT E435302 T1 ATE435302 T1 AT E435302T1 AT 03747881 T AT03747881 T AT 03747881T AT 03747881 T AT03747881 T AT 03747881T AT E435302 T1 ATE435302 T1 AT E435302T1
Authority
AT
Austria
Prior art keywords
rivastigmine
determination
treatment success
apoe genotype
predicting treatment
Prior art date
Application number
AT03747881T
Other languages
English (en)
Inventor
Roger Lane
Mihael Polymeropoulos
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE435302T1 publication Critical patent/ATE435302T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/775—Apolipopeptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
AT03747881T 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken ATE435302T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40169402P 2002-08-07 2002-08-07
PCT/EP2003/008719 WO2004015140A1 (en) 2002-08-07 2003-08-06 Methods for the treatment of dementia based on apo e genotype

Publications (1)

Publication Number Publication Date
ATE435302T1 true ATE435302T1 (de) 2009-07-15

Family

ID=31715721

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03747881T ATE435302T1 (de) 2002-08-07 2003-08-06 Verfahren zur vorhersage des behandlungserfolgs mit rivastigmine basierend auf einer bestimmung des apoe genotyps eines demenzkranken

Country Status (14)

Country Link
US (3) US20060160079A1 (de)
EP (1) EP1529116B1 (de)
JP (1) JP2005534710A (de)
CN (1) CN1681941A (de)
AT (1) ATE435302T1 (de)
AU (1) AU2003266967B2 (de)
BR (1) BR0313588A (de)
CA (1) CA2494585A1 (de)
DE (1) DE60328198D1 (de)
DK (1) DK1529116T3 (de)
ES (1) ES2327914T3 (de)
IL (1) IL166466A0 (de)
PT (1) PT1529116E (de)
WO (1) WO2004015140A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
WO2006014755A2 (en) * 2004-07-20 2006-02-09 Wyeth Methods of identifying patients at risk of developing encephalitis following immunotherapy for alzheimer’s disease
US20060228728A1 (en) * 2005-01-31 2006-10-12 Perlegen Sciences, Inc. Genetic basis of Alzheimer's disease and diagnosis and treatment thereof
US7740593B2 (en) 2005-12-09 2010-06-22 Senorx, Inc Guide block for biopsy or surgical devices
EP2179284B1 (de) 2007-07-31 2016-09-28 Accera, Inc. Verwendung genomischer und ketogener verbindungen zur behandlung von beeinträchtigten kognitiven funktionen
JO3076B1 (ar) * 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9125881B2 (en) 2008-07-03 2015-09-08 Accera, Inc. Monoglyceride of acetoacetate and derivatives for the treatment of neurological disorders
WO2011151359A1 (en) 2010-06-02 2011-12-08 Noscira, S.A. Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
AU2018239433B2 (en) 2017-03-21 2024-02-01 Indiana University Research And Technology Corporation A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof
RS61704B1 (sr) * 2017-05-24 2021-05-31 H Lundbeck As Kombinacija antagonista 5-ht6 receptora i inhibitora acetilholinesteraze za upotrebu u lečenju alchajmerove bolesti kod subpopulacije pacijenata koji nose apoe4 alele
EP3809838B1 (de) * 2018-06-21 2026-04-01 The Jackson Laboratory Genetisch modifizierte mausmodelle der alzheimer-krankheit
WO2020176846A2 (en) * 2019-02-28 2020-09-03 The Rockefeller University Apoe genotyping in cancer prognostics and treatment
JP7689964B2 (ja) 2019-12-13 2025-06-09 インスピルナ,インコーポレーテッド 金属塩及びその使用
CN117886933A (zh) * 2023-12-28 2024-04-16 上海良润生物医药科技有限公司 一种载脂蛋白e检测试剂及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2142300C (en) * 1992-10-13 2005-08-23 Allen D. Roses Methods for detecting alzheimer's disease
CA2111503A1 (en) * 1993-12-15 1995-06-16 Mcgill University Apolipoprotein e polymorphism and alzheimer's disease
FR2765591B1 (fr) * 1997-07-01 2002-08-09 Pasteur Institut Procede de diagnostic de la maladie d'alzheimer
CO4980891A1 (es) * 1997-11-14 2000-11-27 Sanofi Sa Asociacion de principios activos para el tratamiento de la demencia senil de tipo azheimer
JP2000069963A (ja) * 1998-08-31 2000-03-07 Igaku Seibutsugaku Kenkyusho:Kk アポリポプロテインe4特異モノクローナル抗体
IL141762A0 (en) * 1998-10-01 2002-03-10 Novartis Ag New oral formulations
CA2410680A1 (en) * 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Compounds to treat alzheimer's disease

Also Published As

Publication number Publication date
JP2005534710A (ja) 2005-11-17
AU2003266967B2 (en) 2006-11-16
AU2003266967A1 (en) 2004-02-25
US20060160079A1 (en) 2006-07-20
EP1529116A1 (de) 2005-05-11
WO2004015140A1 (en) 2004-02-19
ES2327914T3 (es) 2009-11-05
DE60328198D1 (de) 2009-08-13
US20080214662A1 (en) 2008-09-04
DK1529116T3 (da) 2009-11-09
CN1681941A (zh) 2005-10-12
IL166466A0 (en) 2006-01-15
PT1529116E (pt) 2009-09-10
EP1529116B1 (de) 2009-07-01
CA2494585A1 (en) 2004-02-19
US20100240744A1 (en) 2010-09-23
BR0313588A (pt) 2005-07-12

Similar Documents

Publication Publication Date Title
DE60328198D1 (de) Verfahren zur Vorhersage des Behandlungserfolgs mit Rivastigmine basierend auf einer Bestimmung des ApoE Genotyps eines Demenzkranken
EP1788938A4 (de) System, software und verfahren zur detektion von schlafgestörter atmung mithilfe eines elektrokardiogramms
ATE488251T1 (de) Verfahren zur diagnose und behandlung von schwangerschaftsskomplikationen
EP1463531A4 (de) Verfahren zur hemmung okularer vorgänge
MX2009013649A (es) Variantes geneticas en el cromosoma 15q24 como marcadores para usarse en diagnostico, prognosis y tratamiento de sindrome de exfoliacion y glaucoma.
DE60326748D1 (de) Verfahren zur identifizierung des brustkrebsrisikos
ATE519503T1 (de) Verfahren zur behandlung von patienten mit hepatitis c
WO2004101806A3 (en) Allele-specific expression patterns
ATE503563T1 (de) Blockverhältnisverbesserendes mittel für permeable membran, verfahren zur blockverhältnisverbesserung, permebale membran und wasserbehandlungsverfahren
ATE397098T1 (de) Verfahren zur diagnostik von eierstock endometriose
ATE415488T1 (de) Träger zum nachweis von genen und seine verwendung zur feststellung der wirksamkeit einer interferontherapie
WO2004043232A3 (en) Methods for identifying risk of melanoma and treatments thereof
WO2005014846A3 (en) Methods for identifying risk of breast cancer and treatments thereof
DE602006012456D1 (de) Kühlgerät, steuerverfahren für das kühlgerät und verfahren zur bestimmung von anomalien
DE602005023363D1 (de) Vorrichtung und Verfahren zur Authentifizierung von Blutgefässen
WO2006022619A3 (en) Methods for identifying risk of type ii diabetes and treatments thereof
WO2006028999A3 (en) Assessment of ctla-4 polymorphisms in ctla-4 blockade therapy
DE602005020113D1 (de) Verfahren zur behandlung von akuten rhinosinusitis
ATE487947T1 (de) Verfahren zur diagnose und behandlung auf nr2- peptiden beruhender zerebrovaskulärer ereignisse
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
ATE543429T1 (de) Verfahren zur bestimmung des sympathikus-tonus und messsystem dafür
WO2002053018A3 (en) Method of detecting polymorphisms associated with breast carcinoma in mhc genes
DE602004002692D1 (de) Verfahren zur Herstellung von Topiramate
DE602005016697D1 (de) Molekulardiagnoseverfahren und behandlung von demenz mit lewy-körperchen
WO2005118834A3 (en) Methods for identifying risk of breast cancer and treatment thereof

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1529116

Country of ref document: EP

REN Ceased due to non-payment of the annual fee